By Sherri Oslick —

A note to our readers:  Patent Docs apologizes to our readers for the recent Court Report hiatus.  This Court Reporter was away at trial and has just now been able to come up for air.  We will catch our readers up in the next few postings.  Patent Docs thanks our readers for their patience.

Novartis AG v. Kappos
1:10-cv-00164; filed January 29, 2010 in the
District Court of the District of Columbia

Review and correction of the patent term adjustment
calculation made by the U.S. Patent and Trademark Office for U.S. Patent No.
7,569,337 ("Coumarins Useful as Biomarkers," issued August 4,
2009).  View the complaint here.

Cephalon, Inc. et al. v. Sandoz Inc.
1:10-cv-00175; filed January 26, 2010 in the
District Court of Colorado

• Plaintiffs:  Cephalon, Inc.; Cephalon France
• Defendant:  Sandoz Inc.

Cephalon Inc. et al. v. Sandoz Inc.
1:10-cv-00055; filed January 22, 2010 in the
District Court of Delaware

• Plaintiffs:  Cephalon, Inc.; Cephalon France
• Defendant:  Sandoz Inc.

The complaints in these cases are substantially
identical.  Infringement of U.S.
Patent Nos. 7,297,346 ("Pharmaceutical Formulations of Modafinil,"
issued November 20, 2007), RE37,516 ("Acetamide Derivative Having Defined
Particle Size," issued January 15, 2002), and 7,132,570 ("Method for
the Production of Crystalline Forms of Optical Enantiomers of Modafinil,"
issued November 7, 2006) following a Paragraph IV certification as part of
Sandoz's filing of an ANDA to manufacture a generic version of Cephalon's
Nuvigil® (armodafinil, used to improve wakefulness in patients with excessive
sleepiness associated with obstructive sleep apnea/hypopnea syndrome,
narcolepsy, and shift work sleep disorder).  View the Colorado complaint here.

Purdue Pharma Products LP et al. v. Anchen Pharmaceuticals Inc.
8:10-cv-00103; filed January 22, 2010 in the
Central District of California

• Plaintiffs:  Purdue Pharma Products LP; Napp
Pharmaceutical Group LTD
• Defendant:  Anchen Pharmaceuticals Inc.

Infringement of U.S. Patent Nos. 5,591,452 ("Controlled
Release Formulation," issued January 7, 1997) and 6,326,027 (same title,
issued December 4, 2001) following a Paragraph IV certification as part of
Anchen's filing of an ANDA to manufacture a generic version of plaintiffs'
Ryzolt® (controlled-release tramadol hydrochloride, used to treat moderate to
moderately severe chronic pain).  View the complaint here.

Cephalon, Inc. v. Kappos
1:10-cv-00131; filed January 22, 2010 in the
District Court of the District of Columbia

Review and correction of the patent term adjustment
calculation made by the U.S. Patent and Trademark Office for U.S. Patent No.
7,566,805 ("Modafinil Compositions," issued July 28, 2009).  View the complaint here.

Purdue Pharma Products LP et al. v. Lupin Ltd. et al.
1:10-cv-00049; filed January 21, 2010 in the
District Court of Delaware

• Plaintiffs:  Purdue Pharma Products LP; Napp
Pharmaceutical Group Ltd.
• Defendants:  Lupin Ltd.; Lupin Pharmaceuticals
Inc.

Infringement of U.S. Patent Nos. 6,254,887 ("Controlled
Release Tramadol," issued July 3, 2001) and 7,074,430 ("Controlled
Release Tramadol Tramadol [sic] Formulation," issued July 11, 2006)
following a Paragraph IV certification as part of Lupin's filing of an ANDA to
manufacture a generic version of plaintiffs' Ultram® ER (tramadol
hydrochloride, used to treat moderate to moderately severe chronic pain).  View the complaint here.

Galderma Laboratories LP et al. v. Tolmar Inc.
1:10-cv-00045; filed January 21, 2010 in the
District Court of Delaware

• Plaintiffs:  Galderma Laboratories LP; Galderma
SA; Galderma Research and Development SNC
• Defendant:  Tolmar Inc.

Infringement of U.S. Patent No. 7,579,377 ("Administration
of 6-[3-(1-adamantyl)-4methoxyphenyl]- 2-naphthoic Acid for the Treatment of Dermatological
Disorders," issued August 25, 2009) following a Paragraph IV certification
as part of Tolmar's filing of an ANDA to manufacture a generic version of
Galderma's Differin® gel (adapalene, used in the topical treatment of acne vulgaris).  View the complaint here.

Pfizer Inc. et al. v. Teva Parenteral Medicines Inc. et al.
1:10-cv-00037; filed January 15, 2010 in the
District Court of Delaware

• Plaintiffs:  Pfizer Inc.; Pharmacia Corp.;
Pharmacia & Upjohn Co.; Pharmacia & Upjohn LLC; Pharmacia &
Upjohn Co. LLC; C P Pharmaceuticals International CV
• Defendants:  Teva Parenteral Medicines Inc.; Teva
Pharmaceuticals USA Inc.; Teva Pharmaceutical Industries Ltd.

Infringement of U.S. Patent No. 5,688,792 ("Substituted
Oxazine and Thiazine Oxazolidinone Antimicrobials," issued November 18,
1997) following a Paragraph IV certification as part of Teva's filing of an
ANDA to manufacture a generic version of Pfizer's Zyvox® (linezolid, used to
treat bacterial infections).  View
the complaint here.

Boram Pharm. Co. Ltd. v. Life Technologies Corp.
1:10-cv-00031; filed January 14, 2010 in the
District Court of Delaware

Infringement of U.S. Patent No. 7,319,001 ("High
Throughput System for Producing Recombinant Viruses Using Site-Specific
Recombination," issued January 15, 2008) based on Life Technologies'
manufacture and sale of its BaculoDirect Baculovirus Expression System under
its Invitrogen brand.  View the
complaint here.

Daiichi Sankyo Inc. et al. v. Impax Laboratories Inc.
1:10-cv-00032; filed January 14, 2010 in the
District Court of Delaware

• Plaintiffs:  Daiichi Sankyo Inc.; Genzyme
Corp.
• Defendant:  Impax Laboratories Inc.

Infringement of U.S. Patent Nos. 5,607,669 ("Amine
Polymer Sequestrant and Method of Cholesterol Depletion," issued March 4,
1997) and 5,693,675 ("Alkylated Amine Polymers," issued December 2,
1997) following a Paragraph IV certification as part of Impax's filing of an
ANDA to manufacture a generic version of plaintiffs' Welchol® (colesevelam
hydrochloride, used to treat primary hyperlipidemia and type 2 diabetes
mellitus).  View the complaint here.